Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Robert Mills | M | 71 |
Lung Therapeutics, Inc.
Lung Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Lung Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in the development and commercialization of drugs for lung injury and disease. Its product pipelines include LTI-03 for the treatment of Idiopathic Pulmonary Fibrosis and LTI-01 for Loculated Pleural Effusion. The company was founded by Steven Idell and Andrew Mazar in 2012 and is headquartered in Austin, TX. | 9 Jahre |
R. Session | M | 45 |
Lung Therapeutics, Inc.
Lung Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Lung Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in the development and commercialization of drugs for lung injury and disease. Its product pipelines include LTI-03 for the treatment of Idiopathic Pulmonary Fibrosis and LTI-01 for Loculated Pleural Effusion. The company was founded by Steven Idell and Andrew Mazar in 2012 and is headquartered in Austin, TX. | 5 Jahre |
Aaron Fletcher | M | 44 |
Lung Therapeutics, Inc.
Lung Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Lung Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in the development and commercialization of drugs for lung injury and disease. Its product pipelines include LTI-03 for the treatment of Idiopathic Pulmonary Fibrosis and LTI-01 for Loculated Pleural Effusion. The company was founded by Steven Idell and Andrew Mazar in 2012 and is headquartered in Austin, TX. | 10 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Brian Windsor | M | 57 |
Lung Therapeutics, Inc.
Lung Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Lung Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in the development and commercialization of drugs for lung injury and disease. Its product pipelines include LTI-03 for the treatment of Idiopathic Pulmonary Fibrosis and LTI-01 for Loculated Pleural Effusion. The company was founded by Steven Idell and Andrew Mazar in 2012 and is headquartered in Austin, TX. | - |
Andrew Mazar | M | 62 |
Lung Therapeutics, Inc.
Lung Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Lung Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in the development and commercialization of drugs for lung injury and disease. Its product pipelines include LTI-03 for the treatment of Idiopathic Pulmonary Fibrosis and LTI-01 for Loculated Pleural Effusion. The company was founded by Steven Idell and Andrew Mazar in 2012 and is headquartered in Austin, TX. | - |
Alan Musso | M | 62 |
Lung Therapeutics, Inc.
Lung Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Lung Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in the development and commercialization of drugs for lung injury and disease. Its product pipelines include LTI-03 for the treatment of Idiopathic Pulmonary Fibrosis and LTI-01 for Loculated Pleural Effusion. The company was founded by Steven Idell and Andrew Mazar in 2012 and is headquartered in Austin, TX. | - |
Joseph F. Woelkers | M | - |
Lung Therapeutics, Inc.
Lung Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Lung Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in the development and commercialization of drugs for lung injury and disease. Its product pipelines include LTI-03 for the treatment of Idiopathic Pulmonary Fibrosis and LTI-01 for Loculated Pleural Effusion. The company was founded by Steven Idell and Andrew Mazar in 2012 and is headquartered in Austin, TX. | - |
William Fairey | M | 60 |
Lung Therapeutics, Inc.
Lung Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Lung Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in the development and commercialization of drugs for lung injury and disease. Its product pipelines include LTI-03 for the treatment of Idiopathic Pulmonary Fibrosis and LTI-01 for Loculated Pleural Effusion. The company was founded by Steven Idell and Andrew Mazar in 2012 and is headquartered in Austin, TX. | 2 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 8 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Steven Idell
- Persönliches Netzwerk